Picture of Synlab AG logo

SYAB Synlab AG News Story

0.000.00%
de flag iconLast trade - 00:00
HealthcareAdventurousMid CapSuper Stock

Brief: Synlab 9-Month Adjusted EBITDA At EUR 663 Mln

Nov 10 (Reuters) - SYNLAB AG  SYAB.DE :
    * SYNLAB REPORTS STRONG UNDERLYING PERFORMANCE IN 9M 2022,
CONFIRMS 2022 GUIDANCE AND RELEASES 2023 GUIDANCE
    * SYNLAB AG - ROBUST 9M 2022 PERFORMANCE WITH REVENUE OF EUR
2.5
BILLION
    * STRONG UNDERLYING ORGANIC GROWTH (EXCLUDING COVID-19
RELATED
REVENUES): +6.3% IN 9M 2022 AND +4.1% IN Q3 2022, WELL ABOVE OUR
MID-TERM ORGANIC GROWTH TARGET
    * COVID-19 TESTING REVENUE EUR 720 MILLION IN 9M 2022 (EUR
105
MILLION IN Q3 2022), AS EXPECTED
    * SYNLAB AG - 9M 2022 ADJUSTED EBITDA OF EUR 663 MILLION,
MARGIN
AT 26.0% (EUR 135 MILLION AND 19.3% IN Q3 2022)
    * FY 2022 GUIDANCE CONFIRMED: REVENUE AROUND EUR 3.2 BILLION
AND
ADJUSTED EBITDA MARGIN AT 24-25%
    * FY 2023 GUIDANCE: REVENUE AT AROUND EUR 3.0 BILLION AND
ADJUSTED
EBITDA MARGIN EXPECTED AT 18-20%
    * 9M 2022 NET PROFIT (GROUP SHARE) WAS EUR 191 MILLION.
    * 9M 2022 ADJUSTED NET PROFIT WAS EUR 332 MILLION, A EUR 182
MILLION REDUCTION COMPARED WITH 9M 2021.

Source text for Eikon:  ID:nEQ5qkKcXa 
Further company coverage:  SYAB.DE 
 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on Synlab AG

See all news